John LaMattina, Contributor

Author's details

Name: John LaMattina, Contributor
Date registered: October 19, 2016
URL: http://www.forbes.com/healthcare/

Latest posts

  1. The Biopharmaceutical Cartel And High Drug Prices — April 10, 2019
  2. Outcomes-based Pricing Not A Panacea For High Priced Drugs — March 27, 2019
  3. How Will The Failure Of Biogen’s Alzheimer’s Drug, Aducanumab, Impact R&D? — March 22, 2019
  4. How Will The Failure Of Biogen’s Alzheimer’s Drug, Aducanumab, Impact R&D? — March 22, 2019
  5. The Absurdity Of Avoiding Vaccines — March 8, 2019

Author's posts listings

The Biopharmaceutical Cartel And High Drug Prices

But rather than use tired attacks on the biopharmaceutical industry, upon which we depend to bring much needed treatments and cures, let’s focus the discusion on solutions that can help people pay for medicine while providing the type of revenues neede…

Outcomes-based Pricing Not A Panacea For High Priced Drugs

If the drug doesn’t work, you get your money back. Such a mantra can only improve the industry’s reputation.

How Will The Failure Of Biogen’s Alzheimer’s Drug, Aducanumab, Impact R&D?

The death of an important drug like aducanumab will have both a short and a long term effect on Biogen as a company and especially on R&D.

How Will The Failure Of Biogen’s Alzheimer’s Drug, Aducanumab, Impact R&D?

The death of an important drug like aducanumab will have both a short and a long term effect on Biogen as a company and especially on R&D.

The Absurdity Of Avoiding Vaccines

My brother and I had been sick for a while and we didn’t seem to be getting any better.

The Challenges In Bringing An Anti-Aging Pill To Market

But an anti-aging pill available for the masses is not around the corner. It might not even appear in our lifetime.

Does The NIH Deserve A Piece Of Biopharma’s Profits?

Decades ago, the U.S. believed that investments in research were important for the public good – for our defense, for our health and for our economic prosperity.

Based On Sales Forecasts For 2018 FDA Approved Drugs, Big Pharma Not Just Focused On Blockbusters

What is driving these companies to develop drugs with poorer sales prospects than were previously deemed essential?

Big Pharma Should Accept Cap On Drug Price Increases

By capping price increases to inflation levels, PhRMA can show it cares about patients, drug costs and accessibility of its breakthroughs.

The Demise Of A Once Promising Pancreatic Cancer Drug Is All Too Common

Companies as small as Nivien or as large as Pfizer find the chemical tools and run the experiments that prove or disprove medical hypotheses.

Older posts «

Explore the Archive